What newer medication options can be used to control blood pressure in an adult without contraindications to ACE inhibitors or ARBs?

Newer Medications for Blood Pressure Control

Add a long-acting dihydropyridine calcium-channel blocker (amlodipine 5–10 mg daily) to your current regimen if you are already on an ACE inhibitor or ARB, or initiate combination therapy with an ACE inhibitor/ARB plus amlodipine if starting fresh. This represents the most strongly evidence-based approach for blood pressure control in adults without contraindications to renin-angiotensin system blockade. 1

Preferred First-Line Two-Drug Combinations

• ACE inhibitor or ARB + calcium-channel blocker (CCB) is explicitly endorsed as a preferred initial two-drug regimen by the 2024 European Society of Cardiology, 2025 American Heart Association/American College of Cardiology, and 2020 International Society of Hypertension guidelines, with Grade A/B evidence. 1, 2

• ACE inhibitor or ARB + thiazide diuretic represents an equally valid alternative when a CCB cannot be used, carrying Grade B evidence for blood pressure reduction and cardiovascular protection. 1

• Thiazide diuretic + CCB is the third guideline-recommended pairing, particularly useful when renin-angiotensin system blockade is contraindicated, with Grade A/B evidence for lowering cardiovascular events. 1

Specific Medication Recommendations

Calcium-Channel Blockers (Preferred Add-On)

• Amlodipine 5 mg daily (titrate to 10 mg if needed) is the most extensively studied dihydropyridine CCB with proven cardiovascular outcome benefits when combined with ACE inhibitors or ARBs. 1, 2
• Amlodipine provides 24-hour blood pressure control with once-daily dosing, improving medication adherence. 1
• The combination of amlodipine with an ACE inhibitor or ARB produces synergistic blood pressure reduction through complementary mechanisms (RAAS blockade plus vascular smooth-muscle relaxation). 1

Thiazide-Like Diuretics (Alternative Add-On)

• Chlorthalidone 12.5–25 mg daily is preferred over hydrochlorothiazide due to its longer half-life (40–60 hours vs 6–12 hours) and superior cardiovascular protection demonstrated in landmark trials. 3
• Indapamide 1.25–2.5 mg daily is an acceptable alternative thiazide-like diuretic with comparable antihypertensive efficacy. 3
• When adding a thiazide to an ACE inhibitor or ARB, check serum potassium, sodium, calcium, and uric acid at 2–4 weeks to detect electrolyte disturbances. 3

ACE Inhibitors vs ARBs (When Starting Fresh)

• ACE inhibitors should be considered first choice over ARBs for reducing the risk of myocardial infarction, for primary prevention of heart failure, and for secondary prevention of stroke, based on 2024 Egyptian Cardiology Expert Consensus recommendations. 4
• ACE inhibitors and ARBs show equivalent efficacy for primary prevention of stroke. 4
• ARBs are indicated as alternatives in patients who cannot tolerate ACE inhibitors due to cough (5–10% of patients) or angioedema. 4, 5

Optimal Triple-Therapy Regimen

• When blood pressure remains uncontrolled on two agents, escalate to a three-drug combination: ACE inhibitor/ARB + CCB + thiazide diuretic, with Grade A recommendation. 1, 2
• Single-pill combination formulations are strongly favored to improve adherence. 1, 2

Fourth-Line Agent for Resistant Hypertension

• Spironolactone 25–50 mg daily has the strongest evidence among fourth-line options when blood pressure remains uncontrolled on three optimized first-line agents, provided eGFR ≥ 45 mL/min/1.73 m². 1, 2
• Monitor serum potassium closely when adding spironolactone to an ACE inhibitor or ARB due to increased hyperkalemia risk. 1, 3

Blood Pressure Targets

• Optimal target: systolic 120–129 mmHg and diastolic < 80 mmHg for most adults when therapy is well tolerated, per 2024 ESC guidelines. 1
• Minimum acceptable target: < 140/90 mmHg according to 2020 Hypertension Canada and 2025 AHA/ACC guidelines. 1

Critical Strategies to Avoid

• Do not combine an ACE inhibitor with an ARB—this raises the risk of hyperkalemia and acute kidney injury without added cardiovascular benefit, with Grade B evidence. 1, 3, 2
• Do not use beta-blockers as first-line therapy in uncomplicated hypertension for patients ≥ 60 years unless specific indications exist (coronary artery disease, heart failure, post-MI), as they offer less stroke prevention than other classes. 1, 6
• Do not continue monotherapy at maximal doses when blood pressure remains uncontrolled—guideline-directed combination therapy is required. 1
• Do not prescribe hydrochlorothiazide > 25 mg daily or use thiazides when eGFR < 30 mL/min/1.73 m²; switch to chlorthalidone or a loop diuretic instead. 1, 3

Monitoring and Follow-Up

• Re-evaluate office blood pressure within 3–4 weeks of any therapeutic change to assess achievement of target values. 1
• Encourage home blood pressure monitoring to confirm office readings and evaluate 24-hour control. 1
• If control remains inadequate after optimizing three-drug therapy, evaluate for secondary hypertension causes (primary aldosteronism, renal artery stenosis, obstructive sleep apnea). 1, 2